Iron chelating therapy in adults: How and when?;Les chélateurs du fer : Quand et comment les utiliser chez l'adulte ?

Revue de Medecine Interne

Volumn 34, Issue 1, 2013, Pages 32-38

  Ruivard, M ^a  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

Chelation; Iron; Myelodysplastic syndrome; Sickle cell disease; Thalassemia major

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON;

AGRANULOCYTOSIS; CARDIOVASCULAR EFFECT; DRUG INDICATION; DRUG TOLERABILITY; FERRITIN BLOOD LEVEL; GOLD STANDARD; HEART MUSCLE; HUMAN; IRON CHELATION; IRON OVERLOAD; LIFE EXPECTANCY; LIVER LEVEL; MYELODYSPLASTIC SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; RISK BENEFIT ANALYSIS; SHORT SURVEY; SICKLE CELL ANEMIA; THALASSEMIA MAJOR; TREATMENT OUTCOME;

ANEMIA, SICKLE CELL; BENZOATES; BETA-THALASSEMIA; DEFEROXAMINE; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MAGNETIC RESONANCE IMAGING; MYELODYSPLASTIC SYNDROMES; MYOCARDIUM; PYRIDONES; SIDEROPHORES; TRIAZOLES;

EID: 84871697072     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2012.05.005     Document Type: Short Survey

References (42)

1. Kell D.B. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics 2009, 2:2.
2. Du X., She E., Gelbart T., Truksa J., Lee P., Xia Y., et al. The serine protease TMPRSS6 is required to sense iron deficiency. Science 2008, 320:1088-1092.
3. Ho P.J., Tay L., Lindeman R., Catley L., Bowden D.K. Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias. Intern Med J 2011, 41:516-524.
4. Rund D., Rachmilewitz E. Beta-thalassemia. N Engl J Med 2005, 353:1135-1146.
5. Leitch H.A. Controversies surrounding iron chelation therapy for MDS. Blood Rev 2011, 25:17-31.
6. Majhail N.S., Lazarus H.M., Burns L.J. Iron overload in hematopoietic cell transplantation. Bone Marrow Transplant 2008, 41:997-1003.
7. Lee J.W., Yoon S.S., Shen Z.X., Ganser A., Hsu H.C., Habr D., et al. Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood 2010, 116:2448-2454.
8. Phatak P., Brissot P., Wurster M., Adams P.C., Bonkovsky H.L., Gross J., et al. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology 2010, 52:1671-1679.
9. Fabio G., Minonzio F., Delbini P., Bianchi A., Cappellini M.D. Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH). Blood 2007, 109:362-364.
10. Olivieri N.F., Brittenham G.M. Iron chelating therapy and the treatment of thalassemia. Blood 1997, 89:739-761.
11. Angelucci E., Brittenham G.M., McLaren C.E., Ripalti M., Baronciani D., Giardini C., et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000, 343:327-331.
12. Gandon Y., Olivié D., Guyader D., Aubé C., Oberti F., Sebille V., et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet 2004, 363:357-362.
13. Kirk P., Roughton M., Porter J.B., Walker J.M., Tanner M.A., Patel J., et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009, 120:1961-1968.
14. Breuer W., Ermers M.J., Pootrakul P., Abramov A., Hershko C., Cabantchik Z.I. Desferrioxamine-chelatable iron, a component of serum non-transferrin bound iron, used for assessing chelation therapy. Blood 2001, 97:792-798.
15. Esposito B.P., Breuer W., Sirankapracha P., Pootrakul P., Hershko C., Cabantchik Z.I. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 2003, 102:2670-2677.
16. Pootrakul P., Breuer W., Sametband M., Sirankapracha P., Hershko C., Cabantchik Z.I. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator. Blood 2004, 104:1504-1510.
17. Davis B.A., Porter J.B. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 2000, 95:1229-1236.
18. Tanner M.A., Galanello R., Dessi C., Smith G.C., Westwood M.A., Agus A., et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007, 115:1876-1884.
19. Maggio A., Vitrano A., Capra M., Cuccia L., Gagliardotto F., Filosa A., et al. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial. Br J Haematol 2009, 145:245-254.
20. Link G., Konijn A.M., Breuer W., Cabantchik Z.I., Hershko C. Exploring the " iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med 2001, 138:130-138.
21. Brittenham G.M. Iron chelating therapy for transfusional iron overload. N Engl J Med 2011, 364:146-156.
22. Lucania G., Vitrano A., Filosa A., Maggio A. Chelation treatment in sickle cell-anaemia: much ado about nothing?. Br J Haematol 2011, 154:545-555.
23. Pepe A., Meloni A., Capra M., Cianciulli P., Prossomariti L., Malaventura C., et al. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica 2011, 96:41-47.
24. Maggio A., Vitrano A., Capra M., Cuccia L., Gagliardotto F., Filosa A., et al. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells Mol Dis 2009, 42:247-251.
25. Piga A., Roggero S., Salussolia I., Massano D., Serra M., Longo F. Deferiprone. Ann N Y Acad Sci 2010, 1202:75-78.
26. Ricchi P., Ammirabile M., Costantini S., Cinque P., Lanza A.G., Spasiano A., et al. The impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: a retrospective study. Expert Opin Drug Saf 2010, 9:875-881.
27. Borgna-Pignatti C., Cappellini M.D., De Stefano P., Del Vecchio G.C., Pennell D.J., Porter J.B., et al. Continued improvement in myocardial T2* over 2years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematologica 2011, 96:48-54.
28. Cappellini M.D. Long-term efficacy and safety of deferasirox. Blood Rev 2008, 22:S35-S41.
29. ®) for up to 5years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol 2011, 154:387-397.
30. Cappellini M.D., Bejaoui M., Agaoglu L., Canatan D., Capra M., Cohen A., et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5years' follow-up. Blood 2011, 118:884-893.
31. Gattermann N., Jarisch A., Schlag R., Blumenstengel K., Goebeler M., Groschek M., et al. Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange. Eur J Haematol 2012, 88:260-268.
32. Cermak J., Jonasova A., Vondrakova J., Walterova L., Hochova I., Siskova M., et al. Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome. Hemoglobin 2011, 35:217-227.
33. Wood J.C., Kang B.P., Thompson A., Giardina P., Harmatz P., Glynos T., et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood 2010, 116:537-543.
34. Neufeld E.J. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 2006, 107:3436-3441.
35. Darbari D.S., Kple-Faget P., Kwagyan J., Rana S., Gordeuk V.R., Castro O. Circumstances of death in adult sickle cell disease patients. Am J Hematol 2006, 81:858-863.
36. Stone R.M. How I treat patients with myelodysplastic syndromes?. Blood 2009, 113:6296-6303.
37. http://clinicaltrials.gov/ct2/show/NCT00940602%3Fterm=iron+chelation+myelodysplastic%26rank.
38. Callens C., Coulon S., Naudin J., Radford-Weiss I., Boissel N., Raffoux E., et al. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med 2010, 207:731-750.
39. Rose C., Brechignac S., Vassilief D., Pascal L., Stamatoullas A., Guerci A., et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies). Leuk Res 2010, 34:864-870.
40. Maggio R. Light and shadows in the iron chelation treatment of haematological diseases. BJH 2007, 138:407-421.
41. Kwiatkowski J.L., Kim H.Y., Thompson A.A., Quinn C.T., Mueller B.U., Odame I., et al. Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood 2012, 119:2746-2753.
42. Lescoat G., Léonce S., Pierré A., Gouffier L., Gaboriau F. Antiproliferative and iron chelating efficiency of the new bis-8-hydroxyquinoline benzylamine chelator S1 in hepatocyte cultures. Chem Biol Interact 2012, 195:165-172.